Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Artemis DNA, ITM Isotope Technologies, BriaCell, Caris Life Sciences

NEW YORK – Diagnostic testing firm Artemis DNA said this week that it is opening its first international location in Ho Chi Minh City, Vietnam. Starting this month, the Irvine, California-based firm will offer its genetic testing technology and portfolio, as well as a cancer screening test named Trucheck Pragma in Vietnam. The blood-based screening test was developed by cancer research company Datar Cancer Genetics for the early detection of prostate, breast, ovary, lung, stomach, colon, and pancreatic cancers. Artemis will exclusively distribute Trucheck Pragma in Vietnam. Other terms of the deal were not disclosed.


ITM Isotope Technologies Munich said this week that it has completed enrollment for a Phase III clinical trial of its targeted radionuclide therapy candidate, ITM-11 (n.c.a. 177Lu-edotreotide), in gastroenteropancreatic neuroendocrine tumors. The trial has randomized 300 patients with grade 1 or grade 2 somatostatin receptor-positive neuroendocrine tumors originating in the gastrointestinal tract or pancreas to receive ITM-11 or Novartis' Afinitor (everolimus) with progression-free survival as the primary endpoint, and overall survival as a secondary outcome measure.


The FDA has granted fast track status to BriaCell's cell-based immunotherapy, Bria-IMT, in combination with immune checkpoint inhibitors for metastatic breast cancer. The company is testing Bria-IMT with Incyte's immunomodulator, epacadostat, and retifanlimab in a Phase I/IIa trial in advanced breast cancer. Initial data from the trial showed that patient survival was more than 12 months compared to nine months on previous regimens. "Other patient subsets with possible survival benefit included those who match Bria-IMT at one or more HLA type and those with grade I (well differentiated) or grade II (moderately differentiated) breast cancer," the company said in a statement.


Caris Life Sciences said this week that the University of Kentucky Markey Cancer Center has joined Caris' Precision Oncology Alliance, a worldwide network of cancer centers that collaborate to advance precision oncology and biomarker-driven research. The network now includes 62 cancer centers and academic institutions. Its members have early access to Caris' database and artificial intelligence platform to establish evidence-based standards for cancer profiling and molecular testing in oncology.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.